## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%); PEG 33.66 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.71)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Class Action Reminder from Pomerantz LLP for Investors of Baxter International, Inc. â€“ BAX**
- Source: WTRF | 20251203T120000 | Neutral | Relevance: 99%
- Pomerantz LLP has filed a class action lawsuit against Baxter International, Inc. (NYSE:BAX) and is reminding investors who purchased Baxter securities during the Class Period to contact the firm. The lawsuit alleges securities fraud related to Baxter's voluntary pause of shipments and installations of its Novum LVP medical device, which caused a significant drop in the company's stock price. Investors have until December 15, 2025, to seek appointment as Lead Plaintiff.

**2. BAX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Baxter International, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!**
- Source: WJBF | 20251203T070000 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Baxter International, Inc. (NYSE:BAX) on behalf of investors who suffered losses between February 23, 2023, and July 30, 2025. The lawsuit alleges that Baxter misled investors regarding systemic defects in its Novum LVP product, leading to patient risks and inadequate remedial measures. Investors with losses have until December 15, 2025, to request to be appointed as lead plaintiff.

**3. Baxter International, Inc. (BAX) Investors: December 15, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser**
- Source: mypanhandle.com | 20251201T074500 | Neutral | Relevance: 99%
- Lieff Cabraser Heimann & Bernstein, LLP is encouraging investors in Baxter International, Inc. (NYSE:BAX) to contact them regarding a securities class action lawsuit, with a filing deadline of December 15, 2025. The lawsuit alleges that Baxter made misleading statements and failed to disclose systemic defects in its Novum LVP device, which led to malfunctions and patient injuries or deaths. Following an announcement by Baxter to temporarily pause shipments of the Novum LVP, the company's stock price fell significantly.

**4. Portnoy Law Firm Announces Class Action on Behalf of Baxter International, Inc. Investors**
- Source: GlobeNewswire | 20251202T090000 | Neutral | Relevance: 99%
- The Portnoy Law Firm has announced a class action lawsuit against Baxter International, Inc. (NYSE: BAX) on behalf of investors who purchased securities between February 23, 2022, and July 30, 2025. The lawsuit alleges that Baxter concealed systemic defects in its Novum IQ Large Volume Pump, leading to malfunctions, patient harm, and subsequent financial losses for investors. Investors are encouraged to contact the law firm to discuss their legal rights before the December 15, 2025, lead plaintiff motion deadline.

**5. Baxter International, Inc. (BAX) Investors: December 15, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser**
- Source: Fox 59 | 20251202T074500 | Neutral | Relevance: 99%
- Lieff Cabraser Heimann & Bernstein, LLP encourages investors of Baxter International, Inc. (BAX) who purchased stock between February 23, 2022, and July 30, 2025, to contact them regarding a pending securities class action. The lawsuit alleges that Baxter made misleading statements about its Novum LVP device, which reportedly had systemic defects causing patient injury or death. This led to a significant drop in Baxter's stock price following the announcement of a temporary pause in shipments and installations of the device.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 33.7x requires aggressive growth execution.
2. Elevated short interest (8.6%): bears positioning against stock.
3. Long-term trend broken: trading 30.3% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 33.66 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.3B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 8.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 33.66 |
| Forward P/E | 8.2 |
| Current P/E | 8.0 |
| YoY Growth | -2.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.4% to 0.1% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 (-0.5%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.70x), long-term trend not supportive. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.10% (CS: 55) | Neutral |
| RSI_14 | 46.4 | Neutral |
| MACD Histogram | 0.27 | Bullish |
| vs SMA20 | 1.031x | Above |
| vs SMA50 | 0.915x | Below |
| vs SMA200 | 0.697x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.89
- **Stop Loss:** $17.71 (6.2% risk)
- **Target:** $20.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 805
- **Position Value:** $15,206.45
- **Portfolio %:** 15.21%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite. VIX at 16 is below median, showing calm, but breadth is only moderate and put/call is neutral, suggesting neither strong bullish nor defensive extremes. Key drivers are rising Fed rate-cut odds from soft ADP jobs data, mixed earnings across sectors, and ongoing AI/tech strength offset by caution in cyclicals and banks. Positioning should remain selective and neutral, awaiting more decisive macro or earnings signals.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*